NY-PVH/TOMMY
13.1.2020 08:02:12 CET | Business Wire | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], announces the six finalists in the 2019 Tommy Hilfiger Fashion Frontier Challenge. Now in its second year, the global program aims to support entrepreneurial start-up and scale-up businesses developing solutions that promote inclusive and positive change in fashion. The selection of finalists is a next step in the journey to identify and champion innovative opportunities that support the advancement of the industry. On February 13, 2020, the six finalists will visit Tommy Hilfiger’s Campus of the Future in Amsterdam, the Netherlands, to pitch their business concepts to a jury of internal and external business and sustainability leaders at the global Tommy Hilfiger Fashion Frontier Challenge Final Event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200112005011/en/
“It is inspiring to see the second edition of the Tommy Hilfiger Fashion Frontier Challenge draw so many applicants working towards a more inclusive and sustainable fashion landscape,” said Tommy Hilfiger. “We are committed to championing bright, innovative solutions to some of our industry’s big challenges, and I’m looking forward to returning as a jury member to recognize this year’s entrepreneurs. Their shared optimism and commitment to a positive future should inspire us all in the impact we can make together.”
Over a multi-step four-month process, over 420 applicants were narrowed down to six finalists who were invited to develop and refine their business plans with the support of a dedicated team of social entrepreneur experts at the Campus of the Future. The finalists include:
- Bangladesh-based scale-up, Apon Wellbeing, opens fair-priced shops carrying daily necessities inside factories, with products offered at a 10% discount to external prices and a points scheme that workers collect for free health-insurance and health services.
- American scale-up, Stony Creek Colors , offers natural indigo sustainable crops to small and mid-size tobacco farmers who are at risk of losing their income due to falling tobacco sales. The cash crop provided by Stony Creek Colors enables the farmers to retain their livelihood.
- Dutch start-up, A Beautiful Mess , runs a creative space to assist refugees in realizing social and economic independence by creating sustainable apparel products.
- U.S.-based start-up company Lab 141 creates small batches of made-to-fit clothing using 3D printing. Through these methods, Lab 141 is promoting and bringing to life the concept of “sizeless” fashion.
- Indian scale-up pajama company Sudara develops professional and sewing skills in women who have escaped from or are at high risk of being sex trafficked.
- Hailing from France, scale-up company Constant & Zoe creates functional and fashionable clothing for men, women and children with disabilities.
The prestigious jurors overseeing the final event include:
- Mr. Tommy Hilfiger
- Ankiti Bose, Co-Founder & CEO, Zilingo
- Noor Tagouri, Journalist, Activist and Speaker
- Daniel Grieder, CEO, Tommy Hilfiger Global and PVH Europe
- Martijn Hagman, CFO, Tommy Hilfiger Global & COO, Tommy Hilfiger Global and PVH Europe
- Willemijn Verloop, Founding Partner, Social Impact Venture
- Steven Serneels, CEO and Board Member, EVPA
- Katrin Ley, Managing Director, Fashion for Good
The jury will award €150,000 between two winners to fund the advancement of their business proposals. The winners will also receive a year-long mentorship with Tommy Hilfiger’s and INSEAD’s global experts, as well as a place in the INSEAD Social Entrepreneurship Program (ISEP). An additional €10,000 will be awarded to the finalist team who wins the “Audience Favorite Vote.”
Tommy Hilfiger’s vision is to create fashion that opens minds and closes loops. Find out more about the brand’s long-term sustainability efforts, particularly in the areas of inclusivity and circularity, at: https://global.tommy.com/en_int/about-us-corporate-sustainability .
Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger, #FashionFrontierChallenge, #MakeNewPossible and @TommyHilfiger.
# # #
About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER and TOMMY JEANS , Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER and TOMMY JEANS brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER and TOMMY JEANS retail stores, leading specialty and department stores, select online retailers, and at tommy .com.
About PVH Corp.
PVH sets the standard of style as one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our iconic portfolio includes TOMMY HILFIGER , CALVIN KLEIN , Van Heusen , IZOD , ARROW , Speedo *, Warner’s , Olga and Geoffrey Beene brands, as well as the digital-centric True & Co. intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 38,000 associates operating in over 40 countries and nearly $9.7 billion in annual revenues. That’s the power of PVH.
*The Speedo brand is licensed for North America and the Caribbean in perpetuity from Speedo International Limited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200112005011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
